research use only

BML-284 (Wnt agonist 1) Wnt/beta-catenin activator

Cat.No.S8178

BML-284 (Wnt agonist 1) is a cell permeable Wnt signaling pathway activator, which induces β-catenin- and TCF-dependent transcriptional activity with an EC50 of 0.7 μM.
BML-284 (Wnt agonist 1) Wnt/beta-catenin activator Chemical Structure

Chemical Structure

Molecular Weight: 386.83

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 386.83 Formula

C19H18N4O3·HCl

Storage (From the date of receipt)
CAS No. 2095432-75-8 Download SDF Storage of Stock Solutions

Synonyms AMBMP Smiles COC1=CC=CC(=C1)C2=CC(=NC(=N2)N)NCC3=CC4=C(C=C3)OCO4.Cl

Solubility

In vitro
Batch:

DMSO : 77 mg/mL (199.05 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
Wnt/β-catenin [1]
(Cell-based assay)
In vitro
BML-284 (Wnt agonist 1) does not inhibit the activity of GSK-3β, and may be a useful tool in the study of physiological processes that involve the Wnt pathway[1]. Exposure of human brain endothelial hCMEC/D3 cells to this compound led to an increase in the percentage of cells exhibiting nuclear or perinuclear β-catenin staining after exposure for 16 h to 10 μM (43 ± 2%, p < 0.01, n = 5) and 20 μM (48 ± 5%, p < 0.01, n = 5) compared with that of control (12 ± 1%, n = 5)[2].
In vivo
BML-284 (Wnt agonist 1) mimics the effects of Wnt at the whole-organism level in a Xenopus model (10 μM), and affects Xenopus embryonic head specification[1]. In animal model (Rat renal IR model), this compound significantly lowered serum levels of creatinine, AST, and LDH, inhibited the production of IL-6 and IL-1β, and MPO activities. It reduced iNOS, nitrotyrosine proteins and 4-hydroxynonenal in the kidneys, improving renal regeneration and function while attenuating inflammation and oxidative stress in the kidneys after IR[3].
References

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
What is the formulation of S8178 for in vivo studies?

Answer:
Its IP formula is "2% DMSO+40% PEG 300+2% Tween 80+ddH2O", which can up to 9mg/ml.

Signaling Pathway Map